MIT-001
Phase 2Small molecule
MIT-001 is one of 63 small molecule programs targeting Prevention. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Prevention
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Prograf
VVeloxis Pharmaceuticals
Phase 3
Prolia
OOrganon and Co
Phase 3
Nolvadex
AstraZenecaPhase 2
Orencia
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Yescarta
GileadPhase 2
Ilaris
NovartisPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
BCG Vaccine
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MIT-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMitoImmune Therapeutics